Fig. 4: Pharmacodynamics of 7 × 19 CAR T cells and correlation of plasma IL-7 and CCL19 levels with clinical outcomes. | Cell Discovery

Fig. 4: Pharmacodynamics of 7 × 19 CAR T cells and correlation of plasma IL-7 and CCL19 levels with clinical outcomes.

From: Safety and feasibility of anti-CD19 CAR T cells expressing inducible IL-7 and CCL19 in patients with relapsed or refractory large B-cell lymphoma

Fig. 4: Pharmacodynamics of 7 × 19 CAR T cells and correlation of plasma IL-7 and CCL19 levels with clinical outcomes.The alternative text for this image may have been generated using AI.

a CAR T cell kinetics in the peripheral blood of patients treated with different doses of 7 × 19 CAR T cells during the first 90 days after infusion. b Bar plots showing the peak number of CAR T cells in the blood of responder (CR + PR) or non-responder (SD + PD) (upper) and the cumulative numbers of CAR T cells in the first 28 days of therapy in the blood of responder and non-responder (lower). c Receiver operating characteristic (ROC) curve of cumulative CAR+ T cells as predictor for OS and PFS. d Kaplan-Meier analysis to estimate OS and PFS according to the cut-off value of cumulative CAR+ T cells. e Peak values of plasma IL-7 and CCL19 during the first 28 days after CAR T infusion in patients who achieved CR and PR or without response. Kaplan-Meier analysis to estimate peak values of plasma IL-7 and CCL19 during the first 28 days after CAR T treatment as predictors of OS (f) and PFS (g). The optimal cut-off points for IL-7 and CCL19 were determined by ROC curves and area under the curve. Data are shown as mean ± SD. a–d, f, g n = 39; e n = 26. Two-tailed Student’s t-test (b upper and e), two-tailed Student’s t-test with Welch’s correction (b, lower), z-test (c) and log-rank test (d, f and g). *P < 0.05, **P < 0.01.

Back to article page